Callan Capital LLC Boosts Stock Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Callan Capital LLC increased its position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 222.6% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 661,194 shares of the company’s stock after acquiring an additional 456,207 shares during the period. Callan Capital LLC owned about 0.41% of Neumora Therapeutics worth $6,500,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in NMRA. Amalgamated Bank bought a new stake in shares of Neumora Therapeutics in the 4th quarter worth $29,000. SkyOak Wealth LLC purchased a new stake in shares of Neumora Therapeutics during the second quarter valued at $147,000. Principal Financial Group Inc. purchased a new stake in shares of Neumora Therapeutics during the second quarter valued at $166,000. TD Asset Management Inc increased its holdings in Neumora Therapeutics by 31.6% in the 2nd quarter. TD Asset Management Inc now owns 144,994 shares of the company’s stock worth $1,425,000 after buying an additional 34,800 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in Neumora Therapeutics in the 2nd quarter worth about $566,000. 47.65% of the stock is owned by institutional investors.

Insider Activity at Neumora Therapeutics

In other news, CFO Joshua Pinto sold 31,642 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $11.78, for a total value of $372,742.76. Following the completion of the sale, the chief financial officer now directly owns 154,658 shares of the company’s stock, valued at $1,821,871.24. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CFO Joshua Pinto sold 31,642 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $11.78, for a total value of $372,742.76. Following the completion of the transaction, the chief financial officer now owns 154,658 shares of the company’s stock, valued at $1,821,871.24. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Robert A. Lenz sold 30,788 shares of the stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $11.81, for a total value of $363,606.28. Following the sale, the insider now owns 339,205 shares of the company’s stock, valued at approximately $4,006,011.05. The disclosure for this sale can be found here. In the last ninety days, insiders sold 90,926 shares of company stock worth $1,067,758. 26.40% of the stock is owned by company insiders.

Neumora Therapeutics Trading Up 4.3 %

Shares of Neumora Therapeutics stock opened at $12.73 on Friday. Neumora Therapeutics, Inc. has a 1-year low of $8.33 and a 1-year high of $21.00. The company’s fifty day simple moving average is $11.70 and its 200-day simple moving average is $11.48.

Neumora Therapeutics (NASDAQ:NMRA) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.37). As a group, research analysts predict that Neumora Therapeutics, Inc. will post -1.51 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on NMRA shares. Mizuho assumed coverage on shares of Neumora Therapeutics in a research note on Monday, July 8th. They issued an “outperform” rating and a $20.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 target price on shares of Neumora Therapeutics in a research report on Thursday, September 12th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $29.00 price target on shares of Neumora Therapeutics in a report on Wednesday, September 4th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $22.11.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.